98%
921
2 minutes
20
Background: While glycemic control is essential in critically ill patients, the optimal insulin regimen for patients receiving continuous enteral nutrition (CEN) is unknown.
Objective: This study compares glycemic control in basal/correctional vs basal/bolus/correctional insulin regimens in intensive care unit (ICU) patients receiving CEN.
Methods: This retrospective study included patients ≥18 years old, admitted to the medical critical care service with administration of CEN and ≥20 units of insulin detemir daily for ≥48 hours. Patients receiving non-insulin hypoglycemic agents were excluded. The primary outcome was the comparison of glycemic control, assessed by mean blood glucose and percent of glucose checks in target range. Secondary outcomes included the comparison of hypoglycemia, hyperglycemic emergencies, and glycemic variability between groups.
Results: A total of 100 patients were included, with 50 patients per group. Mean blood glucose and percent of blood glucose checks in the target range were similar between basal/correctional and basal/bolus/correctional groups (204.2 vs 194.2 mg/dL, = 0.2433 and 37.8% vs 43.1%, = 0.3182, respectively). There were no differences in hypoglycemia or hyperglycemic emergencies. Among patients receiving ≥60 units of insulin daily, the basal/bolus/correctional regimen was associated with lower mean blood glucose (197.1 vs 248.5 mg/dL, < 0.0001) and increased glucose checks in target range (43.5% vs 9.1%, = 0.0040) without increased hypoglycemia.
Conclusion And Relevance: Among ICU patients requiring ≥20 units of insulin detemir daily while receiving CEN, basal/correctional and basal/bolus/correctional insulin regimens appear to offer similar glycemic control, but basal/bolus/correctional regimens may improve glycemic control in patients requiring ≥60 units of insulin daily.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10600280251340180 | DOI Listing |
Thromb Res
September 2025
Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Electronic address:
Warfarin is a widely used vitamin K antagonist (VKA) with known pleiotropic effects beyond anticoagulation. Preclinical and case-control evidence suggests that warfarin may affect hematopoiesis, but longitudinal human evidence is lacking. To explore this potential effect, we conducted a post-hoc analysis of participants in the Hokusai-VTE and ENGAGE AF-TIMI 48 trials, which randomized patients to warfarin or the direct oral anticoagulant edoxaban with routine laboratory testing at predefined follow-up visits.
View Article and Find Full Text PDFInt J Orthop Trauma Nurs
August 2025
Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address:
Background: Knee osteoarthritis (KOA) is a prevalent degenerative joint disorder that significantly impairs physical function and daily activities. While conventional treatments focus on symptom management, complementary therapies such as aromatherapy massage have gained attention for their potential benefits.
Objective: This study evaluates the effects of peppermint oil aromatherapy massage on functional impairments in KOA patients.
Am J Clin Hypn
September 2025
Higher Institute of Nursing and Health Technology, Rabat, Morocco.
Gestational trophoblastic tumors (GTTs) encompass a spectrum of neoplastic conditions, including invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Invasive mole, which frequently develops following a complete hydatidiform mole, represents the most common form. A cancer diagnosis constitutes a profoundly destabilizing experience, often resulting in considerable psychological distress.
View Article and Find Full Text PDFRetina
September 2025
Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA.
Purpose: To report outcomes of suprachoroidal hemorrhage (SCH).
Methods: Retrospective non-randomized study of eyes with SCH from two sites (1/1/2013-12/31/2022). The primary outcome was the 6-month change in visual acuity (VA).
J Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDF